Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)
作者
Luboš Petruželka
出处
期刊:Lung Cancer [Elsevier BV] 日期:2012-06-01卷期号:77: S25-S25被引量:1